Intervention1: bococizumab (PF-04950615): 150 mg, every 2 weeks, subcutaneous. The duration of the treatment period will depend upon reaching the targeted number of adjudicated and confirmed CV outcom
Sponsors
Pfizer Limited
Conditions
Health Condition 1: null- Cardiovascular Events /Disease
Phase 3
The Evaluation of Bococizumab (PF-04950615;RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-1)
Active, not recruitingCTRI/2015/07/005955
Target: 17000Updated: 2021-11-24
â??The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects (SPIRE-2)â??
Active, not recruitingCTRI/2015/07/005954
Target: 9000Updated: 2021-11-24